3-Butene-1,2-diol (BDD), a major metabolite of 1,3-butadiene (BD), can readily be oxidized to hydroxymethylvinyl ketone (HMVK), a Michael acceptor. In previous studies, 4-(N-acetyl-l-cystein-S-yl)-1,2-dihydroxybutane (DHB), a urinary metabolite of BD that was used to assess human BD exposure, was suggested to be a metabolite of HMVK, but DHB formation from BDD and the formation of the DHB precursor 4-(N-acetyl-l-cystein-S-yl)-1-hydroxy-2-butanone (HB) have not been previously investigated. In the current study, four HMVK-derived mercapturic acids [DHB, HB, 3-(N-acetyl-l-cystein-S-yl)propan-1-ol (POH), and 3-(N-acetyl-l-cystein-S-yl)propanoic acid (PA)] were identified in the urine of mice and rats given BDD (284-2272 micromol/kg, i.p.) based on GC/MS analyses and comparisons with synthetic standards after esterification and silylation of the carboxyl and hydroxyl groups, respectively. The combined amounts of the mercapturic acids excreted after BDD exposure were dose-dependent and were mostly similar between mice and rats given equivalent doses of BDD. The mercapturic acids accounted for a greater fraction of the administered BDD dose as the dose was lowered, suggesting that HMVK formation represents a prominent route for BDD metabolism in both mice and rats. The major mercapturic acid excreted by mice was DHB, whereas rats excreted equivalent amounts of DHB and HB. The levels of POH or PA were significantly lower in both species relative to DHB or HB. The observed species differences in the excretion of DHB and HB were thought to be due to differences in the capacity of mice and rats to reduce HB to DHB.

3-Butene-1,2-diol (BDD) is a major metabolite of 1,3-butadiene (BD), but the role of BDD in BD toxicity and carcinogenicity remains unclear. In this study, the acute toxicity of BDD was investigated in male Sprague-Dawley rats and B6C3F1 mice. Of the rats given 250 mg/kg BDD, 2 out of 4 died within 24 h; rats experienced hypoglycemia, significant alterations of liver integrity tests, and had lesions in the liver 4 h after treatment, but no lesions were detected in extrahepatic tissues. Rat hepatic GSH and GSSG levels were significantly depleted at both 1 and 4 h after the BDD treatment. Rats administered 200 mg/kg BDD also had liver lesions but no death or hypoglycemia was observed four or 24 h after treatment; these rats had depleted hepatic GSH and GSSG levels at 1 h but not at 4 or 24 h after treatment. Mice administered 250 mg/kg BDD exhibited modest alterations of liver integrity tests, but no death, hypoglycemia, or lesions in any tissue, and hepatic GSH and GSSG levels were depleted at 1 h but not at 4 h. The plasma half-life of BDD was four times longer in rats than in mice. Additional studies in rats showed the depletion of hepatic GSH and GSSG preceded the BDD-induced hypoglycemia and hepatotoxicity. Thus, the long half-life of BDD in rat plasma and the sustained depletion of hepatic GSH and GSSG may in part explain the higher sensitivity of the rat to BDD-induced hepatotoxicity. Furthermore, the results indicate that BDD may play a role in BD-induced toxicity.

This article is available online at http://dmd.aspetjournals.org ABSTRACT:Epidemiological studies have indicated that 1,3-butadiene exposure is associated with an increased risk of leukemia. In human liver microsomes, 1,3-butadiene is rapidly oxidized to butadiene monoxide, which can then be hydrolyzed to 3-butene-1,2-diol (BDD). In this study, BDD and several potential metabolites were characterized in the urine of male B6C3F1 mice and SpragueDawley rats after BDD administration (i.p.

No abstract